Drug-induced cutaneous vasculitis developing during Etanercept treatment for rheumatoid arthritis

Biological disease-modifying anti-rheumatic drugs (bDMARDs) are widely used for the treatment of chronic inflammatory rheumatic diseases. Since the introduction of tumor necrosis factor alpha (TNF-) inhibitors, the treatment of rheumatoid arthritis has been revolutionized. The approach of targeting...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maria N. Chamurlieva, Yulia L. Korsakova, Stefka G. Radenska-Lopovok, Tatiana V. Korotaeva
Formato:	article
Lenguaje:	RU
Publicado:	State Scientific Center of Dermatovenereology and Cosmetology 2021
Materias:	cutaneous vasculitis etanercept biologic dmards case report rheumatoid arthritis Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/91175d6222fa48c88b9edfe7b48b771d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:91175d6222fa48c88b9edfe7b48b771d
record_format	dspace
spelling	oai:doaj.org-article:91175d6222fa48c88b9edfe7b48b771d2021-12-01T22:16:30ZDrug-induced cutaneous vasculitis developing during Etanercept treatment for rheumatoid arthritis0042-46092313-629410.25208/vdv1233https://doaj.org/article/91175d6222fa48c88b9edfe7b48b771d2021-10-01T00:00:00Zhttps://vestnikdv.ru/jour/article/viewFile/1233/1222https://doaj.org/toc/0042-4609https://doaj.org/toc/2313-6294Biological disease-modifying anti-rheumatic drugs (bDMARDs) are widely used for the treatment of chronic inflammatory rheumatic diseases. Since the introduction of tumor necrosis factor alpha (TNF-) inhibitors, the treatment of rheumatoid arthritis has been revolutionized. The approach of targeting TNF- has considerably improved the success of the treatment of rheumatoid arthritis. Their effectiveness has been extensively proven in randomized clinical trials and in clinical practice. Randomized clinical trials and post-marketing studies proved that patients undergoing TNF- inhibitors therapy are at increased risk of infectious disease, bacterial, viral, fungal, opportunistic, oncology and skin adverse effects such as psoriasis and angiitis of the skin. In this case report drug-induced cutaneous vasculitis developing during TNF- inhibitor (Etanercept) treatment for rheumatoid arthritis is described.Maria N. ChamurlievaYulia L. KorsakovaStefka G. Radenska-LopovokTatiana V. KorotaevaState Scientific Center of Dermatovenereology and Cosmetologyarticlecutaneous vasculitisetanerceptbiologic dmardscase reportrheumatoid arthritisDermatologyRL1-803RUVestnik Dermatologii i Venerologii, Vol 97, Iss 4, Pp 113-119 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	cutaneous vasculitis etanercept biologic dmards case report rheumatoid arthritis Dermatology RL1-803
spellingShingle	cutaneous vasculitis etanercept biologic dmards case report rheumatoid arthritis Dermatology RL1-803 Maria N. Chamurlieva Yulia L. Korsakova Stefka G. Radenska-Lopovok Tatiana V. Korotaeva Drug-induced cutaneous vasculitis developing during Etanercept treatment for rheumatoid arthritis
description	Biological disease-modifying anti-rheumatic drugs (bDMARDs) are widely used for the treatment of chronic inflammatory rheumatic diseases. Since the introduction of tumor necrosis factor alpha (TNF-) inhibitors, the treatment of rheumatoid arthritis has been revolutionized. The approach of targeting TNF- has considerably improved the success of the treatment of rheumatoid arthritis. Their effectiveness has been extensively proven in randomized clinical trials and in clinical practice. Randomized clinical trials and post-marketing studies proved that patients undergoing TNF- inhibitors therapy are at increased risk of infectious disease, bacterial, viral, fungal, opportunistic, oncology and skin adverse effects such as psoriasis and angiitis of the skin. In this case report drug-induced cutaneous vasculitis developing during TNF- inhibitor (Etanercept) treatment for rheumatoid arthritis is described.
format	article
author	Maria N. Chamurlieva Yulia L. Korsakova Stefka G. Radenska-Lopovok Tatiana V. Korotaeva
author_facet	Maria N. Chamurlieva Yulia L. Korsakova Stefka G. Radenska-Lopovok Tatiana V. Korotaeva
author_sort	Maria N. Chamurlieva
title	Drug-induced cutaneous vasculitis developing during Etanercept treatment for rheumatoid arthritis
title_short	Drug-induced cutaneous vasculitis developing during Etanercept treatment for rheumatoid arthritis
title_full	Drug-induced cutaneous vasculitis developing during Etanercept treatment for rheumatoid arthritis
title_fullStr	Drug-induced cutaneous vasculitis developing during Etanercept treatment for rheumatoid arthritis
title_full_unstemmed	Drug-induced cutaneous vasculitis developing during Etanercept treatment for rheumatoid arthritis
title_sort	drug-induced cutaneous vasculitis developing during etanercept treatment for rheumatoid arthritis
publisher	State Scientific Center of Dermatovenereology and Cosmetology
publishDate	2021
url	https://doaj.org/article/91175d6222fa48c88b9edfe7b48b771d
work_keys_str_mv	AT marianchamurlieva druginducedcutaneousvasculitisdevelopingduringetanercepttreatmentforrheumatoidarthritis AT yulialkorsakova druginducedcutaneousvasculitisdevelopingduringetanercepttreatmentforrheumatoidarthritis AT stefkagradenskalopovok druginducedcutaneousvasculitisdevelopingduringetanercepttreatmentforrheumatoidarthritis AT tatianavkorotaeva druginducedcutaneousvasculitisdevelopingduringetanercepttreatmentforrheumatoidarthritis
_version_	1718404113601921024

Drug-induced cutaneous vasculitis developing during Etanercept treatment for rheumatoid arthritis

Ejemplares similares